Key Takeaways
- Limagrain has signed a worldwide licensing agreement with Beijing Qi Biodesign Biotechnology to access genome editing technologies for field and vegetable crops.
- The deal gives Limagrain immediate use of a novel CRISPR nuclease, plus future tools from Qi Biodesign’s research pipeline.
- The agreement aligns with the European Union’s updated framework for New Genomic Techniques (NGTs).
- Limagrain is the world’s fourth-largest seed company, reporting 2,500 million euros in 2024-2025 sales with 9,600 employees across 53 countries.
- Qi Biodesign, based in Beijing and backed by 90 million dollars in funding, works with novel DNA nucleases and plant transformation across more than 50 species.
Limagrain has signed a worldwide licensing agreement with Beijing Qi Biodesign Biotechnology Co., Ltd., giving the French seed group access to genome editing technologies for field and vegetable crops. The companies announced the deal on July 31, 2026, opening next-generation breeding tools to one of the world’s largest seed companies.
Limagrain Secures Global Rights to Genome Editing Tools
Under the agreement, Limagrain gains access to Qi Biodesign’s foundational and advanced genome editing technologies. That includes immediate use of a novel CRISPR nuclease, along with future tools coming out of the Beijing company’s research pipeline. The added tools are expected to widen Limagrain’s research capabilities and speed up the development of improved crop varieties.
Expanding Next-Generation Breeding Capabilities
Genome editing has become a key focus in plant breeding. Early CRISPR methods have already shown their value, but the companies note that future crop improvement will call for a broader set of complementary tools suited to specific crops and breeding challenges. Qi Biodesign brings a platform built around novel DNA nucleases, targeted large DNA insertion methods, and plant transformation expertise spanning more than 50 plant species.
A Timely Fit for European Agriculture
The timing lines up with the European Union’s updated regulatory framework for New Genomic Techniques (NGTs). By combining high-performing germplasm with new breeding tools, the seed group aims to better address climate change, disease pressures, and sustainability challenges facing farmers. The partnership also draws on Qi Biodesign’s academic ties and genome-editing expertise.
Limagrain and Qi Biodesign Outline Partnership Goals
“The future of plant breeding will be driven by scientific excellence, technological diversity and strategic partnerships,” said Sebastien Chauffaut, Chief Executive Officer and Chairman of the Scientific Committee at Limagrain.
“We are delighted to collaborate with Limagrain, one of the world’s leading agricultural seed companies,” said Kevin Zhao, Chief Executive Officer and Co-Founder of Qi Biodesign.
Limagrain reported 2,500 million euros in sales in 2024-2025 and ranks as the fourth-largest seed company worldwide, with 9,600 employees across 53 countries. Qi Biodesign, headquartered in Beijing and backed by 90 million dollars in funding, develops genome editing tools for agriculture and plant biotechnology.
